Midland Pharma
A clinical stage pharmaceutical company developing MLP-1236 for the treatment of spinal cord injury and ischemic stroke.
Co-founded by NLC ventures, CEO Peter D. Suzdak, Prof. Zubair Ahmed (Univ. Birmingham) and Prof. Arshad Majid (Univ. Sheffield).
A Clinical stage pharmaceutical company developing novel therapeutics for neurodegenerative disorders such as spinal cord injury and ischemic stroke
A Phase 2b clinical proof-of-concept trial in patients with spinal cord injury will be initiated following the completion of the ongoing financing.
